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INTRODUCTION
Wilson’s  disease  (WD) 
caused by ATP7B mutations is a 
rare autosomal recessive disorder 
of toxic copper accumulation 
resulting in any type of liver 
disease and/or neurological-
psychiatric symptoms or Coombs 
negative hemolytic anemia [1]. 
The Kayser-Fleischer ring in the 
cornea is a characteristic but 
not a specific finding causing 
no alteration of the eye function 
[2]. Hepatocellular carcinoma 
(HCC) was suggested to be 
less frequent in WD than in 
liver diseases of other origin 
[3, 4]. The protective role of 
copper against malignancies 
is debated. Only a few cases of 
cholangiocarcinoma (CCC) in 
WD have been published. Here 
we report on a case with rapidly 
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It has been suggested that hepatobiliary carcinomas are less frequent in Wilson’s disease (WD) than in liver 
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initiation. Rapidly developed tumour metastases were found in the bones, lung and liver (without jaundice). 
Autopsy revealed cholangiocarcinoma as the primary tumour confirmed by strong CK7 positivity and 
glypican-3 negativity. The curiosity of the presented case is the very rapid development of CCC despite 
continuous chelating agent therapy.
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developed CCC in a 47-year-old male WD patient who had 
been followed up and treated with chelating agents throughout 
nine years.
CASE REPORT
This Caucasian male patient presented at the age of 
29 years movement disorders, considered as disharmonic 
vestibular function. Two years later, abnormal liver function 
tests were identified; however, the proper diagnosis of WD was 
established only six years thereafter. The diagnosis was based on 
neuro-psychiatric disorders, the presence of Kayser-Fleischer 
ring, the low ceruloplasmin level (0.11 g/L) and the detection 
of H1069Q homozygous mutation, which is the most frequent 
gene mutation of the ATP7B gene in Hungary. At this time he 
had severe depression, dysarthria, hand tremor and dystonia. 
D-penicillamine treatment was initiated, but after seven years 
it had been changed to trientine due to thrombocytopenia. 
During chelating therapy the neurological symptoms regressed 
and liver tests became normal. The regular ultrasound 
monitoring did not identify  focal liver lesions. 
At 46-years old he was admitted to the hospital because 
of rapidly developed severe back pain. The ultrasound in 
concordance with the physical finding revealed an 80x36x66 
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mm painful paravertebral mass on the right side. The physical 
status was otherwise normal. The X-ray showed no bone 
fracture, but osteolytic lesions in the hip. The laboratory tests 
showed moderate transaminase elevation (AST 55 IU/L, ALT 
73 IU/L), normal alkaline phosphatase (304 IU/L), increased 
gamma-GT (272 IU/L) and CRP (53.1 mg/L) levels. Serum 
bilirubin and blood counts were normal. The tumor markers 
as AFP and CEA were in normal range, but CA19-9 level was 
very high (2996 U/ml).
Fine needle aspiration biopsy revealed an adenocarcinoma. 
Immunohistochemistry was positive for CK and CK7 and 
negative for Vim and TTF1. CT examination revealed multiplex 
foci in the liver and the lungs, and osteolytic metastases in the 
hip. The pancreas was normal and the primary tumor was not 
identified.
The condition of the patient rapidly deteriorated, jaundice 
developed and he died ten days after the admission.
The autopsy showed tumor metastases in the liver, in the 
lungs and bones. The liver was enlarged, filled with greyish 
necrotic tumor mass occupying a large part of the liver 
parenchyma (Fig. 1). The pancreas, bowels, urinary tract were 
normal. 
The histology proved CCC as a primary tumor. Neoplastic 
glands, epithelial proliferation and strong CK7 staining in the 
tumor cells (Figs. 2-4) were identified. Glypican-3 expression 
was undetectable. 
The coronal slides of the brain showed bilateral cavitation 
and softening of the putamen (Fig. 5). The histology identified 
gliosis and many Alzheimer type II cells at the region of the 
softened areas, but no Opalski cells characteristic of WD were 
seen (Fig. 6).
DISCUSSION
The first report on hepatobiliary malignancy in Wilson’s 
disease was published in 1968 [5]. Many reports have been 
published thenceforth; however, most of them dealt with 
Fig. 1. Slice of the liver: cirrhotic liver parenchyma 
with a central hilar tumor mass and multiple 
peripheral tumor nodules are apparent on the slice of 
the liver. Yellowish areas indicate necrosis. Greenish 
color corresponds to severe cholestasis.
Fig. 2. Microscopic examination of the liver 
(H&E, x20): neoplastic glands (arrows) are evident 
embedded in abundant, dense, collagenous stroma. 
Marked nuclear atypia is visible. The non-neoplastic 
liver parenchyma is present (left side).
Fig. 3. Microscopic examination of the liver tumor 
(H&E, x20): hypercellular neoplastic epithelial cell 
proliferation. The lesion forms papillary structures 
with little stroma. Intracytoplasmatic mucin (arrow) 
is detectable in few cells.
Fig. 4. Immunohistochemistry examination of the 
liver tumor: CK7 positivity, intense cytoplasmic 
staining in tumor cells (left). Insert: No glypican-3 
expression was detected (neoplastic glands are at the 
lower part of the picture).
Fig. 5. The coronal slice of the brain: bilateral 
softening of the putamen with cavitation.
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HCC carcinoma in WD patients. Cholangiocarcinoma has 
been published mainly as case reports; there are only two 
retrospective cohort studies on abdominal/hepatobiliary 
malignancies [6, 7].
However, HCC seems to be less frequent in WD patients 
than in cirrhotic patients with other etiology [3, 4]. On the 
other hand, effective chelating therapy may also prevent the 
deterioration of liver disease and the development of cirrhosis 
and HCC [8].
There are conflicting theories regarding the low incidence 
of HCC in WD patients. Formerly it has been suggested that 
copper might have a protective role against HCC in these 
patients [9]. On the contrary, recent data showed that excessive 
amount of copper may cause cell damage via the production 
of reactive oxygen species (ROS) resulting in genetic and 
epigenetic alterations [10]. An elevated level of copper has 
been found in many human malignancies such as colon, lung, 
prostate and breast cancers [11]. Copper may also play a central 
role in the BRAF associated tumorigenesis in melanomas, 
thyroid cancers and hairy cell leukaemias [12]. Thus, chelating 
agents might have an antitumor effect and be effective as an 
anticancer therapy [8, 11, 13].
In our patient CCC developed despite nine years of 
chelating agent therapy (seven years with penicillamine 
and two years with trientine). The patient presented with 
cirrhosis and neurological symptoms at the time of diagnosis. 
His symptoms regressed, and his cirrhosis was compensated 
during the treatment. It is remarkable that CCC developed 
very rapidly, since the regular abdominal ultrasound did not 
identify any sign of malignancy, which became obvious at eight 
months after the last examination.
Several neuropathological findings characteristic of WD 
were present and were confirmed by the autopsy in our patient 
such as bilateral softening of the putamen and the presence 
of Alzheimer type II cells [14]. However, Opalski cells, said 
to be pathognomonic of copper toxicity in the brain, were 
absent, in concordance with a former publication [15]. In our 
patient, CCC developed on a cirrhotic liver, similarly to HCC, 
as previously published [6, 16].
Fig. 6. Microscopic examination of the putamen 
(H&E, x4): the lesion had ill-defined borders, 
inflammatory cells were not present. Near the 
softened areas, scattered Alzheimer type II cells 
(insert, x40, arrows) were seen. Opalski cells 
characteristic of Wilson’s disease were not found.
CONCLUSION
The presented case argues that cholangiocarcinoma may 
develop in well-treated Wilson’s disease patients, on a cirrohic 
liver, similarly to hepatocellular carcinoma. The curiosity of 
this case is the very rapid development of cholangiocarcinoma 
despite continuous chelating agent therapy. 
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